Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$697.73 USD

697.73
961,019

+4.19 (0.60%)

Updated Aug 1, 2025 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (46 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Cerner's (CERN) AbleVets Buyout to Boost Federal Services

by Zacks Equity Research

Cerner (CERN) expects to close the AbleVets deal in the fourth quarter of 2019.

Zacks Equity Research

MCK vs. ALGN: Which Stock Is the Better Value Option?

by Zacks Equity Research

MCK vs. ALGN: Which Stock Is the Better Value Option?

Zacks Equity Research

McKesson (MCK) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Intuitive Surgical (ISRG) Beats on Q3 Earnings, View Solid

by Zacks Equity Research

Intuitive Surgical (ISRG) gains from solid segmental contributions in Q3.

Zacks Equity Research

Top Ranked Value Stocks to Buy for October 18th

by Zacks Equity Research

Here are four stocks with buy rank and strong value characteristics for investors to consider today, October 18th.

Zacks Equity Research

Here's Why You Should Add PRA Health to Your Portfolio Now

by Zacks Equity Research

PRA Health (PRAH) is gaining steadily from expansion in international markets, solid 2019 outlook and growing CRO industry.

Zacks Equity Research

Here's Why You Should Add Allscripts to Your Portfolio Now

by Zacks Equity Research

Allscripts' (MDRX) focus on innovation makes it a worthy investment pick.

Zacks Equity Research

Here's Why You Should Retain Intuitive Surgical for Now

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base. However, margin contraction continues to raise concern.

Zacks Equity Research

Here's Why You Should Hold on to NextGen Healthcare for Now

by Zacks Equity Research

NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.

Zacks Equity Research

Here's Why You Should Hold on to CONMED (CNMD) Stock for Now

by Zacks Equity Research

CONMED (CNMD) raises 2019 revenue and earnings per share guidance.

Zacks Equity Research

Top Ranked Value Stocks to Buy for October 15th

by Zacks Equity Research

Here are four stocks with buy rank and strong value characteristics for investors to consider today, October 15th.

Zacks Equity Research

Here's Why You Should Retain Ecolab (ECL) Stock For Now

by Zacks Equity Research

Ecolab (ECL) continues to gain from robust product portfolio and strong international presence. However, forex remains a woe.

Sreyoshi Mukherjee headshot

Dental Supplies Industry's Near-Term Outlook Looks Bright

by Sreyoshi Mukherjee

With popular trends of digital dentistry and robotics gaining momentum, near-term prospects of the dental industry look promising.

Zacks Equity Research

Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) is gaining steadily from the core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.

Zacks Equity Research

Here's Why You Should Retain Cooper Companies (COO) Stock Now

by Zacks Equity Research

Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions. However, forex continues to remain a concern.

Zacks Equity Research

Is McKesson (MCK) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Here's Why You Should Retain DaVita (DVA) Stock for Now

by Zacks Equity Research

DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, integration risks remain a concern.

Zacks Equity Research

Integer Holdings (ITGR) Boosts Product Line with New Buyout

by Zacks Equity Research

Integer Holdings' (ITGR) buyout is likely to add differentiated capability for complex braided and formed biomedical structures to the company's existing product portfolio.

Zacks Equity Research

Top Ranked Value Stocks to Buy for October 8th

by Zacks Equity Research

Here are four stocks with buy rank and strong value characteristics for investors to consider today, October 8th

Zacks Equity Research

Can McKesson (MCK) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

McKesson (MCK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

MCK vs. ALGN: Which Stock Is the Better Value Option?

by Zacks Equity Research

MCK vs. ALGN: Which Stock Is the Better Value Option?

Zacks Equity Research

Here's Why You Should Invest in Surmodics (SRDX) Stock Now

by Zacks Equity Research

Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.

Zacks Equity Research

Veeva Systems to Improve Patient Outcome With Crossix Buyout

by Zacks Equity Research

The latest acquisition fortifies Veeva Systems' (VEEV) foothold in the HCIT space further.

Zacks Equity Research

Here's Why You Should Retain Cardinal Health Stock for Now

by Zacks Equity Research

Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.

Sreyoshi Mukherjee headshot

Opioid Overdose Crisis in US Likely to Affect These 3 Stocks

by Sreyoshi Mukherjee

Increasing lawsuits against pharmaceutical companies are likely to impact retailers and distributors.